LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) fell 5% during trading on Thursday . The company traded as low as $21.75 and last traded at $21.77. 33,626 shares changed hands during trading, a decline of 80% from the average session volume of 168,950 shares. The stock had previously closed at $22.91.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on LENZ shares. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Raymond James assumed coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an "outperform" rating and a $37.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $35.40.
View Our Latest Analysis on LENZ Therapeutics
LENZ Therapeutics Stock Up 0.4 %
The firm has a fifty day moving average of $31.76 and a two-hundred day moving average of $26.31.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same quarter in the previous year, the company posted ($1.33) earnings per share. As a group, analysts forecast that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.
Institutional Investors Weigh In On LENZ Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of LENZ. SG Americas Securities LLC bought a new position in shares of LENZ Therapeutics in the third quarter worth $107,000. Squarepoint Ops LLC purchased a new stake in LENZ Therapeutics during the 2nd quarter worth about $181,000. MetLife Investment Management LLC bought a new position in LENZ Therapeutics in the 3rd quarter worth about $182,000. GSA Capital Partners LLP purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $246,000. Finally, Jane Street Group LLC purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $286,000. Institutional investors own 54.32% of the company's stock.
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
See Also
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
